Standard Family Office LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Rating) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 776 shares of the company's stock, valued at approximately $59,000.

Other hedge funds have also recently added to or reduced their stakes in the company. D1 Capital Partners L.P. purchased a new position in 10x Genomics in the fourth quarter worth approximately $239,081,000. Sands Capital Management LLC lifted its stake in 10x Genomics by 92.4% in the first quarter. Sands Capital Management LLC now owns 3,201,394 shares of the company's stock worth $243,530,000 after acquiring an additional 1,537,427 shares during the last quarter. BlackRock Inc. lifted its stake in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company's stock worth $696,572,000 after acquiring an additional 1,138,358 shares during the last quarter. ARK Investment Management LLC lifted its stake in 10x Genomics by 27.5% in the first quarter. ARK Investment Management LLC now owns 3,391,338 shares of the company's stock worth $257,979,000 after acquiring an additional 730,472 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of 10x Genomics by 6.9% during the 1st quarter. Baillie Gifford & Co. now owns 7,355,764 shares of the company's stock worth $559,552,000 after buying an additional 477,387 shares during the last quarter. Institutional investors and hedge funds own 74.10% of the company's stock.

10x Genomics Trading Up 5.6 %

Shares of 10x Genomics stock opened at $35.90 on Friday. The company has a fifty day moving average price of $40.25 and a 200 day moving average price of $51.62. 10x Genomics, Inc. has a twelve month low of $30.12 and a twelve month high of $187.85. The stock has a market cap of $4.05 billion, a price-to-earnings ratio of -28.49 and a beta of 1.70.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cowen boosted their price objective on shares of 10x Genomics to $55.00 in a research note on Monday, August 15th. Cowen lifted their target price on shares of 10x Genomics from $50.00 to $55.00 in a research note on Tuesday, August 9th. William Blair cut shares of 10x Genomics from an "outperform" rating to a "market perform" rating in a research note on Friday, July 15th. Bank of America cut shares of 10x Genomics from a "neutral" rating to an "underperform" rating and set a $35.00 price objective for the company. in a research note on Friday, July 15th. Finally, Morgan Stanley lowered their price objective on shares of 10x Genomics from $100.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, August 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and an average target price of $49.25.

Insiders Place Their Bets

In other news, CEO Serge Saxonov sold 2,715 shares of the company's stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $35.19, for a total value of $95,540.85. Following the sale, the chief executive officer now owns 966,102 shares in the company, valued at approximately $33,997,129.38. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Serge Saxonov sold 2,715 shares of 10x Genomics stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $95,540.85. Following the sale, the chief executive officer now owns 966,102 shares of the company's stock, valued at $33,997,129.38. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 1,292 shares of the firm's stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $35.19, for a total value of $45,465.48. Following the completion of the sale, the insider now owns 186,246 shares in the company, valued at $6,553,996.74. The disclosure for this sale can be found here. Insiders have sold 4,994 shares of company stock worth $175,739 in the last quarter. 11.08% of the stock is owned by corporate insiders.

10x Genomics Company Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading

• Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks
• The Auto Market Is Slowly Recovering, These Stocks May Outperform
• Is DocuSign On The Verge Of A Major Reversal?
• Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG – Get Rating).

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.